Safety profile of intravenous iron in inflammatory bowel disease: an up-to-date overview

Spagnuolo, Rocco; Abenavoli, Ludovico; Larussa, Tiziana; Iannelli, Chiara; Pellicano, Rinaldo; Fagoonee, Sharmila; Doldo, Patrizia; Luzza, Francesco

doi:10.23736/s1121-421x.20.02819-6

Cited by 6 publications

(8 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To date, this is the first systematic review to assess the impact of NAFLD on patients with IBD-related hospitalizations. Previous studies [17,33] and systematic reviews have evaluated the risk of developing NAFLD in patients with IBD [12,15,16]. Besides metabolic risk factors common for both diseases, specific IBD-related mechanisms hypothesized to explain this association include micronutrient deficiencies, total parenteral nutrition after bowel resections, and chronic use of IBD medications (particularly steroids and methotrexate) [34].…”

Section: Discussionmentioning

confidence: 99%

“…The effects of IBD on the development of NAFLD are well documented in the medical literature [8,12,15–17]. However, few studies have looked at the potential clinical impact of NAFLD on the clinical course of IBD.…”

Section: Introductionmentioning

confidence: 99%

“…The effects of IBD on the development of NAFLD are well documented in the medical literature [8,12,[15][16][17].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

The impact of nonalcoholic fatty liver disease on inflammatory bowel disease-related hospitalization outcomes: a systematic review

Boustany

Rahhal

Mitri

et al. 2023

European Journal of Gastroenterology &Amp; Hepatology

View full text Add to dashboard Cite

Evidence suggests that patients with inflammatory bowel disease are at higher risk of developing nonalcoholic fatty liver disease (NAFLD). However, there is limited information currently available on how NAFLD may affect the clinical course of IBD. Thus, we conducted a systematic review to evaluate the impact of NAFLD on IBD-related hospitalization outcomes. All observational studies assessing IBD-related hospitalization outcomes in patients with NAFLD were included. Exclusion criteria were studies published in languages other than English or French, or those involving pediatric population. Outcomes included IBD-related hospitalization and readmission rates, need for surgery, length of stay, inpatient mortality, and costs. Overall, 3252 citations were retrieved and seven studies met the inclusion criteria (1 574 937 patients); all were observational, of high quality, and originated in the United States. Measurable outcomes reported in these studies were few and with insufficient similarity across studies to complete a quantitative assessment. Only one study reports NAFLD severity. Two studies suggested a higher rate of hospitalization for patients with both NAFLD and IBD compared to IBD alone (incidence rate ratio of 1.54; 95% confidence interval: 1.33–1.79). This is the first systematic review to date that evaluates any possible association of NAFLD with IBD-related hospitalization outcomes. Despite the paucity and low quality of available data, our findings indicate that NAFLD may be associated with worse outcomes amongst IBD patients (especially Crohn’s disease). Further and higher certainty of evidence is needed for better characterization of such clinical impact.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The impact of nonalcoholic fatty liver disease on inflammatory bowel disease-related hospitalization outcomes: a systematic review

Boustany

Rahhal

Mitri

et al. 2023

European Journal of Gastroenterology &Amp; Hepatology

View full text Add to dashboard Cite

show abstract

“…Liver disease causes significant mortality worldwide, and its prevalence varies across regions, indicating differences in susceptibility [ 1 ]. Previous studies have consistently found strong associations between liver disease and comorbidity such as obesity [ 2 ], type 2 diabetes [ 3 , 4 ], and dyslipidemia [ 5 ]. This comorbidity occurs when two or more diseases are present in the same individual [ 6 , 7 ].…”

Section: Introductionmentioning

confidence: 99%

The regional disparities in liver disease comorbidity among elderly Chinese based on a health ecological model: the China Health and Retirement Longitudinal Study

Gong,

Lin,

et al. 2024

BMC Public Health

View full text Add to dashboard Cite

Purpose This study aimed to investigate the risk factors for liver disease comorbidity among older adults in eastern, central, and western China, and explored binary, ternary and quaternary co-morbid co-causal patterns of liver disease within a health ecological model. Method Basic information from 9,763 older adults was analyzed using data from the China Health and Retirement Longitudinal Study (CHARLS). LASSO regression was employed to identify significant predictors in eastern, central, and western China. Patterns of liver disease comorbidity were studied using association rules, and spatial distribution was analyzed using a geographic information system. Furthermore, binary, ternary, and quaternary network diagrams were constructed to illustrate the relationships between liver disease comorbidity and co-causes. Results Among the 9,763 elderly adults studied, 536 were found to have liver disease comorbidity, with binary or ternary comorbidity being the most prevalent. Provinces with a high prevalence of liver disease comorbidity were primarily concentrated in Inner Mongolia, Sichuan, and Henan. The most common comorbidity patterns identified were "liver-heart-metabolic", "liver-kidney", "liver-lung", and "liver-stomach-arthritic". In the eastern region, important combination patterns included "liver disease-metabolic disease", "liver disease-stomach disease", and "liver disease-arthritis", with the main influencing factors being sleep duration of less than 6 h, frequent drinking, female, and daily activity capability. In the central region, common combination patterns included "liver disease-heart disease", "liver disease-metabolic disease", and "liver disease-kidney disease", with the main influencing factors being an education level of primary school or below, marriage, having medical insurance, exercise, and no disabilities. In the western region, the main comorbidity patterns were "liver disease-chronic lung disease", "liver disease-stomach disease", "liver disease-heart disease", and "liver disease-arthritis", with the main influencing factors being general or poor health satisfaction, general or poor health condition, severe pain, and no disabilities. Conclusion The comorbidities associated with liver disease exhibit specific clustering patterns at both the overall and local levels. By analyzing the comorbidity patterns of liver diseases in different regions and establishing co-morbid co-causal patterns, this study offers a new perspective and scientific basis for the prevention and treatment of liver diseases.

show abstract

“…Although the etiology of IBD has not been clearly specified, intensive studies have linked IBD to metabolic syndrome (MetS), which includes diabetes, obesity, and dyslipidemia [2,3], as they share some common pathophysiological features including inflammation, adipose tissue dysregulation, and gut dysbiosis. MetS treatment has been proposed as a therapeutic approach and/or prevention strategy for patients with IBD [4,5].…”

Section: Introductionmentioning

confidence: 99%

FGF21 Depletion Attenuates Colitis through Intestinal Epithelial IL-22-STAT3 Activation in Mice

Shao

et al. 2023

Nutrients

View full text Add to dashboard Cite

Fibroblast growth factor 21 (FGF21) is a glucose and lipid metabolic regulator. Recent research revealed that FGF21 was also induced by inflammatory stimuli. Its role in inflammatory bowel disease (IBD) has not been investigated. In this study, an experimental IBD model was established in FGF21 knockout (KO) and wild-type (WT) mice by adding 2.5% (wt/vol) dextran sodium sulfate (DSS) to their drinking water for 7 days. The severity of the colitis and the inflammation of the mouse colon tissues were analyzed. In WT mice, acute DSS treatment induced an elevation in plasma FGF21 and a significant loss of body weight in a time-dependent manner. Surprisingly, the loss of body weight and the severity of the colitis induced by DSS treatment in WT mice were significantly attenuated in FGF21 KO mice. Colon and circulating pro-inflammatory factors were significantly lower in the FGF21 KO mice compared to the WT mice. As shown by BrdU staining, the FGF21 KO mice demonstrated increased colonic epithelial cell proliferation. DSS treatment reduced intestinal Paneth cell and goblet cell numbers in the WT mice, and this effect was attenuated in the FGF21 KO mice. Mechanistically, FGF21 deficiency significantly increased the signal transducer and activator of transcription (STAT)-3 activation in intestinal epithelial cells and increased the expression of IL-22. Further study showed that the expression of suppressor of cytokine signaling-2/3 (SOCS 2/3), a known feedback inhibitor of STAT3, was significantly inhibited in the DSS-treated FGF2 KO mice compared to the WT mice. We conclude that FGF21 deficiency attenuated the severity of DSS-induced acute colitis, which is likely mediated by enhancing the activation of the IL-22-STAT3 signaling pathway in intestinal epithelial cells.

show abstract

Safety profile of intravenous iron in inflammatory bowel disease: an up-to-date overview

Cited by 6 publications

References 0 publications

The impact of nonalcoholic fatty liver disease on inflammatory bowel disease-related hospitalization outcomes: a systematic review

The impact of nonalcoholic fatty liver disease on inflammatory bowel disease-related hospitalization outcomes: a systematic review

The regional disparities in liver disease comorbidity among elderly Chinese based on a health ecological model: the China Health and Retirement Longitudinal Study

FGF21 Depletion Attenuates Colitis through Intestinal Epithelial IL-22-STAT3 Activation in Mice

Contact Info

Product

Resources

About